What IDEAYA Biosciences does

IDEAYA Biosciences is a clinical-stage precision medicine oncology company developing targeted therapeutics for molecularly defined solid tumors. Founded in 2015 and headquartered in South San Francisco, IDEAYA applies synthetic lethality, ADC+DDR combinations, MTAP-pathway targeting, and epigenetic inhibition (KAT6/7) to cancers driven by specific genetic alterations. The company has 13 clinical-stage programs across four platform pillars: PKC inhibition (darovasertib for uveal melanoma), ADC+DDR combinations (IDE849 DLL3 ADC, IDE034 B7H3/PTK7 bispecific ADC, IDE161 PARG inhibitor), MTAP-pathway targeting (IDE397 MAT2A inhibitor, IDE892 MTA-cooperative PRMT5 inhibitor), and KAT6/7 dual inhibition (IDE574). Four registrational trials are ongoing for darovasertib in uveal melanoma, with an NDA accepted by the FDA in April 2026 under the RTOR program for first-line HLA-A*02:01-negative metastatic disease and Breakthrough Therapy Designation in the neoadjuvant setting.

The company is pre-commercial and generates no product revenue, with current income sourced from collaboration milestones, license payments, and grants. Q1 2026 collaboration revenue was $10.88M, and the company reported approximately $1.05B in cash plus marketable securities at year-end 2025, augmented by a $345M June 2026 public offering. IDEAYA retains U.S. rights to darovasertib (Servier holds ex-U.S. rights via a $210M upfront deal) and is building a specialty oncology commercial organization led by a newly appointed Chief Commercial Officer targeting a 2027 U.S. launch in HLA-A*02:01-negative metastatic uveal melanoma - a setting with no approved therapies. The company also pursues combination and co-development collaborations with Roche, AstraZeneca, Pfizer, Jiangsu Hengrui, and Biocytogen, while operating global Phase 1/2 trials across North America, Europe, Australia, South America, and Asia.

Name

IDEAYA Biosciences

Legal name

IDEAYA Biosciences, Inc.

Website

https://ideayabio.com

Company type

Public

Founded year

2015

Operating status

Operating

Headcount range

101–250 employees

Short description

IDEAYA Biosciences is a clinical-stage precision medicine oncology company developing targeted small molecules and antibody-drug conjugates for genetically defined solid tumors, with a lead registrational asset (darovasertib) in uveal melanoma under FDA review.

Ownership category

akta.pro rank

Product category

Precision Oncology Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI)

Keywords

• Precision oncology therapeutics
• Targeted cancer therapies
• Synthetic lethality drugs
• Antibody drug conjugates
• Kinase inhibitor oncology

Headquarters

HQ city

South San Francisco

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

1. Potential future product sales: IDEAYA is pre-commercial and does not yet generate product revenue. The company is advancing darovasertib toward a potential FDA approval and commercial launch in 2027 for metastatic uveal melanoma. Future revenue would derive from product sales in the U.S., subject to regulatory approval.
2. Milestone payments from Servier (darovasertib ex-U.S.): IDEAYA received a $210 million upfront payment from Servier under an exclusive ex-U.S. licensing agreement for darovasertib, with up to $320 million in remaining potential regulatory and commercial milestone payments, plus double-digit royalties on ex-U.S. net sales.
3. Partnership and milestone revenue: Additional revenue may come from existing and future partnerships including milestone payments upon achievement of clinical, regulatory, and commercial objectives (e.g., Roche collaboration, Jiangsu Hengrui licensing, Biocytogen milestones).
4. Q3 2025 collaboration revenue: IDEAYA reported Q3 2025 net income and revenue, partly attributable to the $210 million upfront payment from Servier recognized in prior periods, as well as ongoing collaboration and grant revenue from partnerships.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels7 records

Core offering

IDEAYA Biosciences is a clinical-stage precision medicine oncology company that discovers and develops targeted small molecules and antibody-drug conjugates for patients with molecularly defined solid tumors. Its pipeline spans PKC inhibition (darovasertib) for uveal melanoma, DLL3 and bispecific B7H3/PTK7 ADCs for solid tumors, and synthetic lethality programs (MAT2A, PRMT5, PARG, KAT6/7 inhibitors) for MTAP-deleted and other genetically defined cancers. The company is pre-commercial and preparing for potential FDA approval and 2027 launch of darovasertib in metastatic uveal melanoma.

Product overview

IDEAYA Biosciences is a precision medicine oncology company with a pipeline of clinical-stage targeted therapies focused on synthetic lethality and antibody-drug conjugates (ADCs) for molecularly defined solid tumor indications. The core pipeline consists of darovasertib (PKC inhibitor for uveal melanoma), IDE849 (DLL3 TOP1 ADC for small cell lung cancer), IDE034 (B7H3/PTK7 bispecific ADC), IDE161 (PARG inhibitor), IDE397 (MAT2A inhibitor), IDE892 (PRMT5 inhibitor), and IDE574 (KAT6/7 dual inhibitor). The company is preparing for commercial launch of darovasertib with NDA under FDA review, while advancing multiple Phase 1 and registrational clinical trials across its ADC+DDR and MTAP pathway programs.

Differentiator

Problem solved

Functional benefit

Products and services

• Darovasertib A potential first-in-class protein kinase C (PKC) inhibitor targeting the primary oncogenic driver in uveal melanoma. Currently in late-stage registrational trials across all stages of uveal melanoma, with NDA under FDA review for metastatic disease.
• IDE849 A DLL3-targeting TOP1 antibody-drug conjugate (ADC) for DLL3-expressing tumors including small cell lung cancer and neuroendocrine carcinomas. Phase 1/2 study evaluating monotherapy and combination with durvalumab or IDE161.
• IDE034 A first-in-class B7H3/PTK7 bispecific TOP1 antibody-drug conjugate designed to preferentially target tumor cells co-expressing both proteins. Phase 1 trial for locally advanced/metastatic solid tumors.
• IDE161 An oral PARG (Poly(ADP-ribose) glycohydrolase) inhibitor designed to block DNA repair when combined with TOP1-based ADCs, creating synthetic lethality. Phase 1 study in advanced solid tumors.
• IDE397 A potential first-in-class and best-in-class MAT2A inhibitor for MTAP-deleted solid tumors. Reduces SAM availability to suppress methyltransferase activity in MTAP-deleted cancer cells. Phase 1 study ongoing.
• IDE892

Quantifiable outcome

• Darovasertib + crizotinib achieved 6.9-month median PFS vs 3.1 months for investigator's choice (HR: 0.42, p<0.0001), representing a 58% reduction in risk of disease progression in first-line HLA-A*02:01-negative metastatic uveal melanoma (Phase 2/3 OptimUM-02 trial, n=313 patients)
• +4 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Six partnerships are on record, tiered core and minor.

• RochecoreStrategic or Co-development Partner · 3 June 2026IDEAYA entered into a clinical collaboration with Roche to evaluate IDE892 (MTA-cooperative PRMT5 inhibitor) in combination with RG6505 (Roche's Phase 1 pan-RAS inhibitor) in MTAP-deleted pancreatic ductal adenocarcinoma. The collaboration targets the genetic co-alterations of MTAP and KRAS in this indication. IDEAYA sponsors the study while Roche provides RG6505.
• AstraZenecaminorStrategic or Co-development Partner · 9 April 2026IDEAYA announced a clinical collaboration with AstraZeneca to evaluate IDE849 (DLL3 TOP1 ADC) in combination with AstraZeneca's Imfinzi (durvalumab) for extensive-stage small cell lung cancer. IDEAYA sponsors the global Phase 1 study while AstraZeneca supplies Imfinzi. Enrollment is ongoing across North America, Europe, Australia, South America, and Asia.
• ServiercoreStrategic or Co-development Partner · 1 January 2025IDEAYA entered into an exclusive ex-U.S. licensing agreement with Servier for darovasertib. IDEAYA retains all rights in the U.S. and is eligible to receive a total of $320 million in regulatory and commercial milestones plus double-digit royalties on all ex-U.S. net sales. Servier paid a $210 million upfront payment. The companies jointly conducted the Phase 2/3 OptimUM-02 registrational trial. Servier terminated the collaboration in December 2025 per some reports.
• Jiangsu Hengrui PharmaceuticalscoreStrategic or Co-development Partner · 1 January 2025IDEAYA has an exclusive licensing agreement with Jiangsu Hengrui Pharmaceuticals for IDE849, a DLL3 TOP1 ADC. IDEAYA controls worldwide rights outside of Greater China. The Phase 1/2 trial for IDE849 is conducted by Jiangsu Hengrui Pharmaceuticals, which has reached therapeutic dose levels with early signs of efficacy.
• BiocytogencoreStrategic or Co-development Partner · 1 July 2024IDEAYA has an option and license agreement with Biocytogen for IDE034, a B7H3/PTK7 bispecific TOP1 ADC. Biocytogen originally developed IDE034 and licensed it to IDEAYA in July 2024. The first patient dosing milestone triggered a $5 million payment to Biocytogen. IDEAYA controls worldwide development and commercialization rights.
• PfizercoreStrategic or Co-development Partner · 1 January 2019IDEAYA has a clinical trial collaboration and drug supply agreement with Pfizer for crizotinib (Pfizer's oral c-MET inhibitor). IDEAYA is evaluating darovasertib in combination with crizotinib in metastatic uveal melanoma. Crizotinib is used as the combination partner in the OptimUM-02 registrational trial.

Scale indicators10 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Nuvalent: Clinical-stage precision oncology company developing targeted therapies for cancer, including kinase inhibitors for specific driver mutations. Similar precision medicine approach and clinical-stage profile to IDEAYA.
• Relay Therapeutics: Precision medicine oncology company using computational approaches to develop targeted therapies for genetically defined cancers, including programs in PI3K and other precision oncology targets.
• Accent Therapeutics: Precision oncology company developing small molecule therapies targeting RNA-modifying proteins for cancer treatment — comparable as a clinical-stage precision oncology developer with biomarker-driven patient selection.
• Monte Rosa Therapeutics: Clinical-stage biotechnology company developing molecular glue degraders for precision oncology targets, including programs in GSPT1 and other cancer-specific vulnerabilities — similar synthetic lethality and precision oncology profile.
• Tango Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based therapies, with a lead PRMT5 inhibitor program targeting MTAP-deleted cancers — directly comparable to IDEAYA's MTAP pathway strategy.
• Black Diamond Therapeutics: Precision oncology company developing allosteric, mutation-targeted therapies for genetically defined cancers — directly comparable in precision oncology drug development approach and clinical-stage profile.
• Theseus Pharmaceuticals: Clinical-stage precision oncology company developing targeted kinase inhibitors for cancer, including programs in resistance mutations — comparable precision oncology approach and clinical-stage profile.
• Repare Therapeutics: Precision oncology company leveraging synthetic lethality to develop targeted therapies for genomically-defined cancers, including programs in DNA damage response and synthetic lethal targets — closely aligned with IDEAYA's synthetic lethality platform.
• Foghorn Therapeutics: Clinical-stage precision oncology company targeting chromatin regulatory systems, including programs in BRG1/BRM and other epigenetic targets — comparable to IDEAYA's KAT6/7 epigenetic program and broader synthetic lethality approach.

Broad incumbents

• Schrödinger: Computational drug discovery company with a precision oncology pipeline, offering a broader platform play with multiple partnered and internal programs. Less focused on synthetic lethality than IDEAYA but comparable in using computational methods to advance precision oncology drug development.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• Xx.com/IdeayaB27412
• YouTubeyoutube.com/@IDEAYABiosciences
• LinkedInlinkedin.com/company/ideaya-biosciences
• Facebookfacebook.com/1056786244370603

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds8 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDEAYA Biosciences